抗高血压药物类别和单片药组合在肥胖患者中的频率:一项为期8年的回顾性研究
相关实验视频
Updated: Jan 17, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
909
Beata Moczulska1, Karolina Osowiecka2, Leszek Gromadziński1
1Department of Cardiology and Internal Medicine, School of Medicine, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
Journal of clinical hypertension (Greenwich, Conn.)
|September 22, 2025
概括
患有高血压的肥胖患者增加了多种抗高血压药物和特定类型的比如β阻塞剂的使用. 然而,单片药组合 (SPC) 的使用仍然很低,尽管对高血压管理的指导方针建议.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 肥胖是高血压和心血管疾病的重要危险因素.
- 现有的高血压指南缺乏针对肥胖患者的具体建议.
- 自2018年以来,为高血压管理推使用单片药物组合 (SPC).
研究的目的:
- 评估8年来患有高血压的肥胖患者的抗高血压治疗模式.
- 分析高风险小组的处方习惯,具体治疗指导有限.
- 为了比较2020年之前和之后的治疗模式.
主要方法:
- 对233名肥胖高血压患者的病历进行了回顾性分析.
- 从住院患者中选择了患者,以便在减肥手术前进行手术前评估.
- 确定了两个队列:在2020年之前被诊断出来的和在2020年或之后被诊断出来的.
主要成果:
- 2020年后观察到的三种或更多抗高血压药物的使用增加.
- 2020年后,β-阻断剂和血管激素受体阻断剂的处方率将会更高.
- 产品简介使用率较低:两种药物组合35.6%,三种药物组合11.2%,时间没有显著增加.
- 在2020年之后,将SGLT2抑制剂引入治疗.
结论:
- 当前高血压指南与肥胖患者的实际处方实践之间存在差异.
- 坚持对肥胖个体高血压的治疗建议可以改善结果.
- 需要进一步的研究来优化这种人群的药物坚持和治疗结果.
相关概念视频
Drug Dosing: Obese Patients
225
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
225
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
248
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
248
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169
Hypertension IV: Drug Therapy and Lifestyle Modifications
624
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
624
Drug Dosing: Geriatric Patients
228
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
228
Bioequivalence of Drugs: Drugs with Multiple Indications
151
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
151

